[{"id":"e5c5e3c9-2ffb-460f-a19f-d1731cde39ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT03897036","created_at":"2021-01-18T19:11:35.946Z","updated_at":"2024-07-02T16:35:50.335Z","phase":"Phase 1","brief_title":"Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)","source_id_and_acronym":"NCT03897036","lead_sponsor":"Senhwa Biosciences, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e silmitasertib (CX-4945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-04-18"},{"id":"bb831b25-4b1e-44f8-a3dc-5bc7d5306158","acronym":"","url":"https://clinicaltrials.gov/study/NCT02354261","created_at":"2021-01-18T11:12:06.637Z","updated_at":"2024-07-02T16:36:42.308Z","phase":"Phase 2b","brief_title":"Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)","source_id_and_acronym":"NCT02354261","lead_sponsor":"HedgePath Pharmaceuticals, Inc.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itraconazole • Tolsura (SUBA-itraconazole)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/07/2015","start_date":" 08/07/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-08-05"},{"id":"b9a2bdff-ff07-4e10-adff-f14635a883a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111187","created_at":"2021-01-18T09:45:47.717Z","updated_at":"2024-07-02T16:37:02.137Z","phase":"Phase 1","brief_title":"A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer","source_id_and_acronym":"NCT02111187","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Odomzo (sonidegib)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 01/18/2017","primary_completion_date":" 01/18/2017","study_txt":" Completion: 01/18/2017","study_completion_date":" 01/18/2017","last_update_posted":"2019-03-07"},{"id":"79383924-a193-49a9-829a-e82787434ada","acronym":"","url":"https://clinicaltrials.gov/study/NCT02115828","created_at":"2021-01-18T09:47:28.933Z","updated_at":"2024-07-02T16:37:08.789Z","phase":"Phase 1","brief_title":"A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy","source_id_and_acronym":"NCT02115828","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AKT1 • GLI1","pipe":" | ","alterations":" GLI1 expression","tags":["AKT1 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2018-07-20"}]